ADU-1604 / Sairopa - LARVOL DELTA

ADU-1604, a novel CTLA-4 blocking antibody, to modulate pharmacodynamic markers in patients with PD1 relapse/refractory melanoma. (ASCO 2024) - "The clinical relevance of CTLA-4 blockade was demonstrated by the approval of ipilimumab for the treatment of melanoma, both in the adjuvant as well as metastatic settings. ADU-1604 Phase 1 dose-escalation data indicates clinical activity in line with what has been observed with other CTLA-4 blocking antibodies. Importantly, no DLTs and very limited safety signals were reported during the study. Dose expansion at 225 mg dose is ongoing in subjects with advanced-stage, relapsed/refractory melanoma who relapsed or were refractory to a prior anti-PD-1/PD-L1 therapy."

Clinical • IO biomarker • PK/PD data • Gastrointestinal Disorder • Hepatitis B • Hepatology • Infectious Disease • Melanoma • Oncology • Solid Tumor • CD4 • CD8 • CD80 • CD86 • ICOS • PD-1

ADU-1604, a novel CTLA-4 blocking antibody modulates pharmacodynamic markers in PD1 relapse/refractory melanoma patients (SITC 2023) - "The clinical relevance of CTLA-4 blockade was demonstrated by the approval of ipilimumab (YERVOY®) for the treatment of melanoma, both in the adjuvant as well as metastatic settings. Importantly, no DLTs have been reported during the study. Updated safety, biomarker and response assessments will be reported at the meeting."

Clinical • IO biomarker • PK/PD data • Melanoma • Oncology • Solid Tumor • CD4 • CD8 • CD80 • CD86 • ICOS

Safety of ADU-1604 in Adults With Metastatic Melanoma (clinicaltrials.gov) - P1; N=4; Terminated; Sponsor: Aduro Biotech, Inc.; Active, not recruiting ➔ Terminated; Study terminated due to business realignment

Trial termination

Safety of ADU-1604 in Adults With Metastatic Melanoma (clinicaltrials.gov) - P1; N=4; Active, not recruiting; Sponsor: Aduro Biotech, Inc.; Recruiting ➔ Active, not recruiting; N=31 ➔ 4; Trial completion date: Sep 2020 ➔ Sep 2019; Trial primary completion date: May 2020 ➔ Aug 2019

Clinical • Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date